<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="3-part\PMC7068796\results\search\disease\results.xml">
  <result pre="the T-cell epitopes of the CSP; and the &quot;S�? for" exact="hepatitis" post="B surface antigen (HBsAg). In Africa, this latter vaccine"/>
  <result pre="In contrast, more progress has been achieved regarding prevention of" exact="leishmaniasis" post="by vaccine, which also started with the use of"/>
  <result pre="use has been extended with success to the immunotherapy of" exact="cancer" post="based on unleashing immune checkpoints. Vaccines and sanitation were"/>
  <result pre="variolation comes from China, where dried pustules from patients with" exact="smallpox" post="were blown into the noses of healthy people or"/>
  <result pre="who was himself variolized, inoculated material obtained from lesions of" exact="cowpox" post="in an 8-year-old child, who showed protection when challenged"/>
  <result pre="showed protection when challenged with material obtained from pustules of" exact="smallpox" post="infection. Jenner did not know at that time that"/>
  <result pre="The work of Jenner then reproduced variolation but with the" exact="cowpox" post="virus, generating mild lesions that give high cross-protection (10,"/>
  <result pre="vaccinate the USA army. To date, the biological origin of" exact="vaccinia virus" post="is uncertain, and it has been suggested that a"/>
  <result pre="intensified campaign promoted by the WHO in 1966. In 1977," exact="smallpox" post="was considered eradicated (8). Rinderpest was the second global"/>
  <result pre="attenuated vaccine and, together with Koch, an attenuated vaccine against" exact="anthrax" post="bacillus, in 1881 (15). A few years later, Diphtheria"/>
  <result pre="Ramon, in 1920, Behring described an efficacious vaccine against both" exact="diphtheria" post="and tetanus, composed of the inactivated toxins, with alumina"/>
  <result pre="attenuated Mycobacterium bovis and obtained the attenuated BCG vaccine against" exact="tuberculosis" post="in 1924 (17). A vaccine composed by the toxoids"/>
  <result pre="by the toxoids of Diphtheria and Tetanus and inactivated Bordetella" exact="pertussis" post="was only launched in the USA in 1948, but"/>
  <result pre="and Tetanus continued to be used and a new acellular" exact="pertussis" post="vaccine was only licensed in the USA in 1996"/>
  <result pre="in the USA in 1996 (18). In 1930, inactivated fractionated" exact="influenza" post="vaccines started to be produced in embryonated eggs, which"/>
  <result pre="and Influenza (2). A very effective live attenuated vaccine against" exact="yellow fever," post="composed of three 17D sub-strains, was developed in Cuba"/>
  <result pre="immunosuppressed individuals, and promoted outbreaks of poliovirus 2 vaccine-associated paralytic" exact="poliomyelitis" post="(21). For these reasons, in some countries, the inactivated"/>
  <result pre="techniques enabled the production of synthetic surface antigens of the" exact="hepatitis" post="B virus (22) and of the HPV L1-derived virus-like"/>
  <result pre="(2). In summary, after live vaccination was first used against" exact="smallpox" post="in 1796, enormous efforts were made in the early"/>
  <result pre="conjugated to proteins or not, and to recombinant vaccines against" exact="hepatitis" post="B and HPV and other organisms. The Delay in"/>
  <result pre="occurred in the early 1900's. Ross demonstrated that mosquitoes transmit" exact="malaria" post="parasites in 1897 (27). Carlos Chagas described how big"/>
  <result pre="agreement, Leishman and Donovan had described the parasite that caused" exact="visceral leishmaniasis" post="in Indian soldiers already in 1903 (29). Another factor"/>
  <result pre="Leishman and Donovan had described the parasite that caused visceral" exact="leishmaniasis" post="in Indian soldiers already in 1903 (29). Another factor"/>
  <result pre="in India, Ross studied Malaria, while Leishman and Donovan described" exact="visceral leishmaniasis." post="Saul Adler, on the other hand, discovered the vertebrate"/>
  <result pre="the ones affected in earlier centuries (31). However, Malaria and" exact="leishmaniasis" post="are still neglected diseases and have only recently attracted"/>
  <result pre="the 1980's. The absence of clear correlates of protection for" exact="malaria" post="was considered an important problem to overcome. Several tests"/>
  <result pre="controlled human Malaria infection (CHMI) has been used to test" exact="malaria" post="vaccines and drugs and to evaluate the products in"/>
  <result pre="been ethically accepted. Furthermore, the development of synthetic vaccines against" exact="malaria" post="started in the 1980's, and field assays were conducted"/>
  <result pre="in humans all support the feasibility of developing highly effective" exact="malaria" post="vaccines. Although 5,400 antigens have been described, the precise"/>
  <result pre="remain uncertain (37). The urgent need for a tool for" exact="malaria" post="prevention promoted a joint initiative of funding agencies, private"/>
  <result pre="the use of insecticide-impregnated bed nets are already contributing to" exact="malaria" post="control, a highly efficient vaccine is still needed. PEV"/>
  <result pre="the future lyophilized formulation (45). It is formulated as a" exact="hepatitis" post="B surface antigen (HBsAg) fused with the CPS central"/>
  <result pre="Human Plasmodium falciparum pre-erythrocytic RTS,S CPS central repeat fused to" exact="hepatitis" post="B surface antigen adjuvanted with ASO1 adjuvant (monophosphoryl lipid"/>
  <result pre="antigen called VMP-001 (54). Furthermore, going back to the first" exact="malaria" post="vaccine, 100% protection was also obtained in six North"/>
  <result pre="children and showed a 36% reduction of severe cases of" exact="malaria" post="(36, 54). However, this study raised a number of"/>
  <result pre="order to check the sustained efficacy. Vaccine efficacy against severe" exact="malaria" post="was sustained and proved after 6 or 7 years"/>
  <result pre="31% in younger children (3–5 years). However, VE against mild" exact="malaria" post="was 23.7% in the older children and 15.5% in"/>
  <result pre="addition, in the highest transmission center, an increase in clinical" exact="malaria" post="was measured in older children (VE = −30.3%). Fifteen"/>
  <result pre="Although an increase in the incidence of uncomplicated cases of" exact="malaria" post="was noticed in the vaccinated subjects, a delayed peak"/>
  <result pre="vaccinated subjects, a delayed peak for the incidence of severe" exact="malaria" post="was also detected. This bias trend of increasing clinical"/>
  <result pre="at the very early stage of liver infection. Therefore, clinical" exact="malaria" post="was not expected to occur in vaccinated subjects. It"/>
  <result pre="subjects. It may be argued that natural exposure to repeated" exact="malaria" post="is needed to acquire immunity. However, chemoprevention of malaria"/>
  <result pre="repeated malaria is needed to acquire immunity. However, chemoprevention of" exact="malaria" post="only promoted a small increase in clinical cases (58)."/>
  <result pre="health community expects the development and licensing, by 2030, of" exact="malaria" post="vaccines with protective efficacy of at least 75%. Hence,"/>
  <result pre="with protective efficacy of at least 75%. Hence, the available" exact="malaria" post="vaccines are considered only as a complementary tool for"/>
  <result pre="52). Although the AMA-1 antigen recently demonstrated efficacy against clinical" exact="malaria" post="provoked by parasites that showed genetic identity with the"/>
  <result pre="of a multivalent vaccine (54). TBV Vaccines Recent concerns of" exact="malaria" post="spreading worldwide have focused interest on prevention with transmission-blocking"/>
  <result pre="Malaria in Sub Saharan Africa (66). Vaccines Against Leishmaniasis Visceral" exact="leishmaniasis" post="(VL) is a disease with a wide geographical distribution"/>
  <result pre="year (70). There are two epidemiological types of VL: zoonotic" exact="visceral leishmaniasis" post="(ZVL), which is transmitted from dogs to humans, and"/>
  <result pre="(70). There are two epidemiological types of VL: zoonotic visceral" exact="leishmaniasis" post="(ZVL), which is transmitted from dogs to humans, and"/>
  <result pre="(ZVL), which is transmitted from dogs to humans, and anthroponotic" exact="visceral leishmaniasis" post="(AVL), which is transmitted from human to human, both"/>
  <result pre="which is transmitted from dogs to humans, and anthroponotic visceral" exact="leishmaniasis" post="(AVL), which is transmitted from human to human, both"/>
  <result pre="cachexia. Splenomegaly and/or hepatomegaly also occur, which may lead to" exact="anemia" post="due to the persistent state of inflammation and, eventually,"/>
  <result pre="inflammation and, eventually, death. It is also characterized by progressive" exact="suppression" post="of the cellular immune response and hypergammaglobulinemia (31, 74)."/>
  <result pre="Israel (9, 78). Although most field studies focus on human" exact="cutaneous leishmaniasis" post="(CL), there have been no clinical trials of first-generation"/>
  <result pre="(9, 78). Although most field studies focus on human cutaneous" exact="leishmaniasis" post="(CL), there have been no clinical trials of first-generation"/>
  <result pre="2003 (80–84) and Leishtec® in 2008 (85). In Europe, where" exact="visceral leishmaniasis" post="is also a canid zoonosis, two other vaccines were"/>
  <result pre="(80–84) and Leishtec® in 2008 (85). In Europe, where visceral" exact="leishmaniasis" post="is also a canid zoonosis, two other vaccines were"/>
  <result pre="was the first vaccine licensed for the prevention of canine" exact="visceral leishmaniasis" post="(Table 1) (75, 83, 88). It is composed of"/>
  <result pre="the first vaccine licensed for the prevention of canine visceral" exact="leishmaniasis" post="(Table 1) (75, 83, 88). It is composed of"/>
  <result pre="(20.48%), and apathy (24.17%) (109). Local swelling reactions, vomit, and" exact="diarrhea" post="were only detected in 15.90, 2.4, and 1.5% of"/>
  <result pre="and allergic reactions were noted only in 0.1% and transient" exact="alopecia" post="at the injection site in 0.28% of the injected"/>
  <result pre="of efficacy were not severe disease or deaths in canine" exact="visceral leishmaniasis," post="as were used for evaluation of Leishmune® previously (100,"/>
  <result pre="dog culling, Leishtec® may not reduce the canine incidence of" exact="leishmaniasis" post="in areas of high transmission and may have no"/>
  <result pre="Vaccination Against VL Although different degrees of prevention of canine" exact="leishmaniasis" post="are currently achievable, depending on which of the four"/>
  <result pre="(79). This performance was expected for a first-generation vaccine against" exact="leishmaniasis" post="(3). The second human vaccine that was tested in"/>
  <result pre="in Balb/c and C57 Bl6 mice vaccinated against visceral and" exact="cutaneous leishmaniasis" post="(140, 142–144) and in dogs treated against ZVL (148)."/>
  <result pre="Balb/c and C57 Bl6 mice vaccinated against visceral and cutaneous" exact="leishmaniasis" post="(140, 142–144) and in dogs treated against ZVL (148)."/>
  <result pre="(150). Giardiasis is a common cause of waterborne outbreaks of" exact="diarrhea" post="due to the transmission of Giardia cysts. It is"/>
  <result pre="Giardia cysts. It is a zoonotic disease. Clinical manifestations of" exact="giardiasis" post="include diarrhea, loss of weight, anorexia, and lethargy, both"/>
  <result pre="as a preventive tool (151). It was shown to attenuate" exact="giardiasis" post="symptoms and to prevent cysts spreading in cats and"/>
  <result pre="One exception is the vaccine against Variola, which is a" exact="viral disease" post="known since the 16th BCE that was successfully eradicated"/>
  <result pre="safety criteria. The situation is better in the case of" exact="visceral leishmaniasis," post="which is a canid zoonosis. The licensed second-generation vaccines"/>
  <result pre="1.PolandGAMorseD. Improving the public health: the U.S. recommendation for universal" exact="influenza" post="immunization. Vaccine. (2010) 28:2799–800. 10.1016/j.vaccine.2010.03.00220346856 2.De GregorioERappuoliR. From empiricism"/>
  <result pre="development. Nat Rev Immunol. (2014) 14:505–14. 10.1038/nri369424925139 3.Palatnik-de-SousaCB. Vaccines for" exact="leishmaniasis" post="in the fore coming 25 years. Vaccine. (2008) 26:1709–24."/>
  <result pre="Infect. (2003) 5:553–60. 10.1016/S1286-4579(03)00075-312758285 16.KaufmannSHE. Remembering emil von behring: from" exact="tetanus" post="treatment to antibody cooperation with phagocytes. mBio. (2017) 8:e00117-17."/>
  <result pre="Lond Engl. (2019) 398:148–58. 10.1016/S0140-6736(19)31279-6 22.ValenzuelaPMedinaARutterWJAmmererGHallBD. Synthesis and assembly of" exact="hepatitis" post="B virus surface antigen particles in yeast. Nature. (1982)"/>
  <result pre="(accessed August 15, 2019). 30.ChiaWNGohYSRéniaL. Novel approaches to identify protective" exact="malaria" post="vaccine candidates. Front Microbiol. (2014) 5:586. 10.3389/fmicb.2014.0058625452745 31.Palatnik-de-SousaCBDayMJ. One"/>
  <result pre="Dis Soc Am. (2015) 60:930–6. 10.1093/cid/ciu95425452593 36.van den BergMOgutuBSewankamboNKBiller-AndornoNTannerM. RTS,S" exact="malaria" post="vaccine pilot studies: addressing the human realities in large-scale"/>
  <result pre="10.1186/s13063-019-3391-731151473 37.TujuJKamuyuGMurungiLMOsierFHA. Vaccine candidate discovery for the next generation of" exact="malaria" post="vaccines. Immunology. (2017) 152:195–206. 10.1111/imm.1278028646586 38.FreundJThomsonKJSommerHEWalterAWSchenkeinEL. Immunization of rhesus"/>
  <result pre="Am J Med Sci. (1973) 266:169–77. 10.1097/00000441-197309000-000024583408 40.StanisicDIMcCarthyJSGoodMF. Controlled human" exact="malaria" post="infection: applications, advances, and challenges. Andrews-polymenis HL, editor. Infect"/>
  <result pre="the immunodominant surface antigen on the sporozoite of the human" exact="malaria" post="parasite Plasmodium falciparum. Science. (1984) 225:593–9. 10.1126/science.62043836204383 45.KesterKECummingsJFOfori-AnyinamOOckenhouseCFKrzychUMorisPet al.."/>
  <result pre="10.1126/science.62043836204383 45.KesterKECummingsJFOfori-AnyinamOOckenhouseCFKrzychUMorisPet al.. Randomized, double-blind, phase 2a trial of falciparum" exact="malaria" post="vaccines RTS,S/AS01B and RTS,S/AS02A in malaria-naive adults: safety, efficacy,"/>
  <result pre="RTS S Clinical Trials PartnershipEfficacy and safety of the RTS,S/AS01" exact="malaria" post="vaccine during 18 months after vaccination: a phase 3"/>
  <result pre="al.. A clinical trial of prime-boost immunisation with the candidate" exact="malaria" post="vaccines RTS,S/AS02A and MVA-CS. Vaccine. (2006) 24:2850–9. 10.1016/j.vaccine.2005.12.04116434127 49.AllouecheAMilliganPConwayDJPinderMBojangKDohertyTet"/>
  <result pre="24:2850–9. 10.1016/j.vaccine.2005.12.04116434127 49.AllouecheAMilliganPConwayDJPinderMBojangKDohertyTet al.Protective efficacy of the RTS,S/AS02 Plasmodium falciparum" exact="malaria" post="vaccine is not strain specific. Am J Trop Med"/>
  <result pre="Am J Trop Med Hyg. (2003) 68:97–101. 10.4269/ajtmh.2003.68.9712556156 50.EnosseSDobañoCQuelhasDAponteJJLievensMLeachAet al.RTS,S/AS02A" exact="malaria" post="vaccine does not induce parasite CSP T cell epitope"/>
  <result pre="on genotypes of P. falciparum in adults participating in a" exact="malaria" post="vaccine clinical trial. PLoS ONE. (2009) 4:e784910.1371/journal.pone.000784919924281 52.BejonPOgadaEMwangiTMilliganPLangTFeganGet al.."/>
  <result pre="follow-up following a phase 2b randomized trial of the candidate" exact="malaria" post="vaccines FP9 ME-TRAP and MVA ME-TRAP among children in"/>
  <result pre="with plasmodium berghei. PLoS ONE. (2010) 5:e12294. 10.1371/journal.pone.001229420808868 54.HeppnerDG. The" exact="malaria" post="vaccine—status quo 2013. Travel Med Infect Dis. (2013) 11:2–7."/>
  <result pre="(accessed September 2, 2019). 57.TintoHOtienoWGesaseSSorghoHOtienoLLihelukaEet al.. Long-term incidence of severe" exact="malaria" post="following RTS,S/AS01 vaccination in children and infants in Africa:"/>
  <result pre="Med Hyg. (1991) 45:297–308. 10.4269/ajtmh.1991.45.2971928564 61.GentonBBetuelaIFelgerIAl-YamanFAndersRFSaulAet al.. A recombinant blood-stage" exact="malaria" post="vaccine reduces Plasmodium falciparum density and exerts selective pressure"/>
  <result pre="blocking vaccine against Plasmodium falciparum: an open label study in" exact="malaria" post="naïve adults. PLoS ONE. (2016) 11:e0163144. 10.1371/journal.pone.016314427749907 65.MiuraKSwihartBJDengBZhouLPhamTPDioufAet al.."/>
  <result pre="expressed in E. coli as a lead antigen for placental" exact="malaria" post="vaccine development. NPJ Vaccines. (2018) 3:28. 10.1038/s41541-018-0064-630038803 67.collab: Leishmaniasis"/>
  <result pre="PLoS ONE. (2012) 7:e35671. 10.1371/journal.pone.003567122693548 71.Di MuccioTScaloneABrunoAMarangiMGrandeRArmignaccoOet al.Epidemiology of imported" exact="leishmaniasis" post="in Italy: implications for a European endemic country. PLoS"/>
  <result pre="Amazonas State, Brazil. Parasit Vectors. (2015) 8:18010.1186/s13071-015-0789-225889808 74.KumarRNylénS. Immunobiology of" exact="visceral leishmaniasis." post="Front Immunol. (2012) 3:251. 10.3389/fimmu.2012.0025122912637 75.Dantas-TorresFSolano-GallegoLBanethGRibeiroVMdePaiva-Cavalcanti MOtrantoD. Canine leishmaniosis"/>
  <result pre="differences. Trends Parasitol. (2012) 28:531–8. 10.1016/j.pt.2012.08.00722995719 76.DyeC. The logic of" exact="visceral leishmaniasis" post="control. Am J Trop Med Hyg. (1996) 55:125–30. 10.4269/ajtmh.1996.55.1258780448"/>
  <result pre="Trends Parasitol. (2012) 28:531–8. 10.1016/j.pt.2012.08.00722995719 76.DyeC. The logic of visceral" exact="leishmaniasis" post="control. Am J Trop Med Hyg. (1996) 55:125–30. 10.4269/ajtmh.1996.55.1258780448"/>
  <result pre="A deAMenzIPalatnikMLavorC. Decrease of the incidence of human and canine" exact="visceral leishmaniasis" post="after dog vaccination with leishmune in Brazilian endemic areas."/>
  <result pre="deAMenzIPalatnikMLavorC. Decrease of the incidence of human and canine visceral" exact="leishmaniasis" post="after dog vaccination with leishmune in Brazilian endemic areas."/>
  <result pre="83.Borja-CabreraGPSantosFNBauerFSParraLEMenzIMorgadoAAet al.. Immunogenicity assay of the leishmune vaccine against canine" exact="visceral leishmaniasis" post="in Brazil. Vaccine. (2008) 26:4991–7. 10.1016/j.vaccine.2008.07.02918675868 84.Palatnik-de-SousaCBBarbosa A deFOliveiraSMNicoDBernardoRRSantosWRet"/>
  <result pre="al.. Immunogenicity assay of the leishmune vaccine against canine visceral" exact="leishmaniasis" post="in Brazil. Vaccine. (2008) 26:4991–7. 10.1016/j.vaccine.2008.07.02918675868 84.Palatnik-de-SousaCBBarbosa A deFOliveiraSMNicoDBernardoRRSantosWRet"/>
  <result pre="of quillaja saponaria mixture as adjuvants for the FML-vaccine against" exact="visceral leishmaniasis." post="Vaccine. (2006) 24:3909–20. 10.1016/j.vaccine.2006.02.03416556475 90.PalatnikCBBorojevicRPreviatoJOMendonça-PreviatoL. Inhibition of Leishmania donovani"/>
  <result pre="The fucose-mannose ligand-ELISA in the diagnosis and prognosis of canine" exact="visceral leishmaniasis" post="in Brazil. Am J Trop Med Hyg. (1999) 61:296–301."/>
  <result pre="fucose-mannose ligand-ELISA in the diagnosis and prognosis of canine visceral" exact="leishmaniasis" post="in Brazil. Am J Trop Med Hyg. (1999) 61:296–301."/>
  <result pre="J Trop Med Hyg. (1999) 61:296–301. 10.4269/ajtmh.1999.61.29610463683 96.Palatnik-de-SousaCBParaguai-de-SouzaEGomesEMSoares-MachadoFCLuzKGBorojevicR. Transmission of" exact="visceral leishmaniasis" post="by blood transfusion in hamsters. Braz J Med Biol"/>
  <result pre="Trop Med Hyg. (1999) 61:296–301. 10.4269/ajtmh.1999.61.29610463683 96.Palatnik-de-SousaCBParaguai-de-SouzaEGomesEMSoares-MachadoFCLuzKGBorojevicR. Transmission of visceral" exact="leishmaniasis" post="by blood transfusion in hamsters. Braz J Med Biol"/>
  <result pre="(2003) 21:2474–84. 10.1016/S0264-410X(03)00032-X12744881 104.RafatiSNakhaeeATaheriTTaslimiYDarabiHEravaniDet al.. Protective vaccination against experimental canine" exact="visceral leishmaniasis" post="using a combination of DNA and protein immunization with"/>
  <result pre="21:2474–84. 10.1016/S0264-410X(03)00032-X12744881 104.RafatiSNakhaeeATaheriTTaslimiYDarabiHEravaniDet al.. Protective vaccination against experimental canine visceral" exact="leishmaniasis" post="using a combination of DNA and protein immunization with"/>
  <result pre="de SouzaEHashimoto OkadaLYde A TrivellatoFAKawasakiJKAet al.. Effective immunotherapy against canine" exact="visceral leishmaniasis" post="with the FML-vaccine. Vaccine. (2004) 22:2234–43. 10.1016/j.vaccine.2003.11.03915149782 109.ParraLEBorja-CabreraGPSantosFNSouzaLOPPalatnik-de-SousaCBMenzI. Safety"/>
  <result pre="SouzaEHashimoto OkadaLYde A TrivellatoFAKawasakiJKAet al.. Effective immunotherapy against canine visceral" exact="leishmaniasis" post="with the FML-vaccine. Vaccine. (2004) 22:2234–43. 10.1016/j.vaccine.2003.11.03915149782 109.ParraLEBorja-CabreraGPSantosFNSouzaLOPPalatnik-de-SousaCBMenzI. Safety"/>
  <result pre="10.1016/j.vaccine.2003.11.03915149782 109.ParraLEBorja-CabreraGPSantosFNSouzaLOPPalatnik-de-SousaCBMenzI. Safety trial using the Leishmune vaccine against canine" exact="visceral leishmaniasis" post="in Brazil. Vaccine. (2007) 25:2180–6. 10.1016/j.vaccine.2006.11.05717239495 110.BigaevaEDoornEvLiuHHakE. Meta-analysis on"/>
  <result pre="109.ParraLEBorja-CabreraGPSantosFNSouzaLOPPalatnik-de-SousaCBMenzI. Safety trial using the Leishmune vaccine against canine visceral" exact="leishmaniasis" post="in Brazil. Vaccine. (2007) 25:2180–6. 10.1016/j.vaccine.2006.11.05717239495 110.BigaevaEDoornEvLiuHHakE. Meta-analysis on"/>
  <result pre="saponin enriched-Leishmune vaccine versus immunochemotherapy in dogs with natural canine" exact="visceral leishmaniasis." post="Vaccine. (2010) 28:597–603. 10.1016/j.vaccine.2009.09.07119800443 112.SantosFNBorja-CabreraGPMiyashiroLMGrechiJReisABMoreiraMABet al.. Immunotherapy against experimental"/>
  <result pre="Vaccine. (2010) 28:597–603. 10.1016/j.vaccine.2009.09.07119800443 112.SantosFNBorja-CabreraGPMiyashiroLMGrechiJReisABMoreiraMABet al.. Immunotherapy against experimental canine" exact="visceral leishmaniasis" post="with the saponin enriched-Leishmune vaccine. Vaccine. (2007) 25:6176–90. 10.1016/j.vaccine.2007.06.00517630055"/>
  <result pre="(2010) 28:597–603. 10.1016/j.vaccine.2009.09.07119800443 112.SantosFNBorja-CabreraGPMiyashiroLMGrechiJReisABMoreiraMABet al.. Immunotherapy against experimental canine visceral" exact="leishmaniasis" post="with the saponin enriched-Leishmune vaccine. Vaccine. (2007) 25:6176–90. 10.1016/j.vaccine.2007.06.00517630055"/>
  <result pre="to evaluate the efficacy of the Leish-Tec® vaccine against canine" exact="visceral leishmaniasis" post="in an endemic area of Brazil. Vaccine. (2016) 34:2233–9."/>
  <result pre="evaluate the efficacy of the Leish-Tec® vaccine against canine visceral" exact="leishmaniasis" post="in an endemic area of Brazil. Vaccine. (2016) 34:2233–9."/>
  <result pre="Field trial of efficacy of the Leish-tec® vaccine against canine" exact="leishmaniasis" post="caused by Leishmania infantum in an endemic area with"/>
  <result pre="JesusCSouza BMP daSLarangeiraDFFragaDBMet al.. Comparison of two commercial vaccines against" exact="visceral leishmaniasis" post="in dogs from endemic areas: IgG, and subclasses, parasitism,"/>
  <result pre="BMP daSLarangeiraDFFragaDBMet al.. Comparison of two commercial vaccines against visceral" exact="leishmaniasis" post="in dogs from endemic areas: IgG, and subclasses, parasitism,"/>
  <result pre="profiles similar to those of Leish-Tec® and Leishmune® vaccines against" exact="visceral leishmaniasis." post="Parasit Vectors. (2016) 9:47210.1186/s13071-016-1752-627577735 126.MoreiraMLCosta-PereiraCAlvesMLRMarteletoBHRibeiroVMPeruhype-MagalhãesVet al.. Vaccination against canine"/>
  <result pre="timeline kinetics of cytokine-mediated cellular immunity in dogs vaccinated against" exact="visceral leishmaniasis." post="BMC Vet Res. (2015) 11:92. 10.1186/s12917-015-0397-625880646 128.de LimaVMFIkedaFARossiCNFeitosaMMVasconcelosRONunesCMet al.."/>
  <result pre="in dogs vaccinated with Leishmune in an endemic area for" exact="visceral leishmaniasis." post="Vet Immunol Immunopathol. (2010) 135:296–302. 10.1016/j.vetimm.2009.12.00820132994 129.AraújoMSSde AndradeRASathler-AvelarRTeixeira-CarvalhoAAndradeMCViannaLRet al.."/>
  <result pre="anti-Leishmania (Leishmania) chagasi IgG subclass patterns following immunization against canine" exact="visceral leishmaniasis" post="using Leishvaccine and Leishmune. Vaccine. (2009) 27:1008–17. 10.1016/j.vaccine.2008.11.10419110023 130.MartinVVouldoukisIMorenoJMcGahieDGueguenSCuisinierA-M."/>
  <result pre="(Leishmania) chagasi IgG subclass patterns following immunization against canine visceral" exact="leishmaniasis" post="using Leishvaccine and Leishmune. Vaccine. (2009) 27:1008–17. 10.1016/j.vaccine.2008.11.10419110023 130.MartinVVouldoukisIMorenoJMcGahieDGueguenSCuisinierA-M."/>
  <result pre="(2015) 208:94–100. 10.1016/j.vetpar.2015.01.00325620293 133.MorenoJ. Assessment of Vaccine-induced immunity against canine" exact="visceral leishmaniasis." post="Front Vet Sci. (2019) 6:168. 10.3389/fvets.2019.0016831214607 134.SotoMRequenaJMQuijadaLAlonsoC. Multicomponent chimeric"/>
  <result pre="6:168. 10.3389/fvets.2019.0016831214607 134.SotoMRequenaJMQuijadaLAlonsoC. Multicomponent chimeric antigen for serodiagnosis of canine" exact="visceral leishmaniasis." post="J Clin Microbiol. (1998) 36:58–63. 10.1128/JCM.36.1.58-63.19989431920 135.CarcelénJIniestaVFernández-CotrinaJSerranoFParejoJCCorralizaIet al.. The"/>
  <result pre="10.1016/j.vaccine.2009.07.06919666153 136.KhalilEAGMusaAMModabberFEl-HassanAM. Safety and immunogenicity of a candidate vaccine for" exact="visceral leishmaniasis" post="(Alum-precipitated autoclaved Leishmania major + BCG) in children: an"/>
  <result pre="136.KhalilEAGMusaAMModabberFEl-HassanAM. Safety and immunogenicity of a candidate vaccine for visceral" exact="leishmaniasis" post="(Alum-precipitated autoclaved Leishmania major + BCG) in children: an"/>
  <result pre="calmette-guérrin, a candidate vaccine for visceral leishmaniasis: safety, skin-delayed type" exact="hypersensitivity" post="response and dose finding in healthy volunteers. Trans R"/>
  <result pre="hydrolase from Leishmania (L.) donovani is an antigen diagnostic for" exact="visceral leishmaniasis." post="Mol Biochem Parasitol. (2002) 120:315–9. 10.1016/S0166-6851(02)00010-511897139 140.NicoDMartins AlmeidaFMaria MottaJSoares"/>
  <result pre="nucleoside hydrolase (NH36) domains induce T-cell cytokine responses in human" exact="visceral leishmaniasis." post="Front Immunol. (2017) 8:227. 10.3389/fimmu.2017.0022728321221 146.ColerRNDuthieMSHofmeyerKAGuderianJJayashankarLVergaraJet al.. From mouse"/>
  <result pre="mouse to man: safety, immunogenicity and efficacy of a candidate" exact="leishmaniasis" post="vaccine LEISH-F3+GLA-SE. Clin Transl Immunol. (2015) 4:e35. 10.1038/cti.2015.626175894 147.collab:"/>
  <result pre="hydrolase DNA vaccine as an aid in immunotherapy of canine" exact="visceral leishmaniasis." post="Procedia Vaccinol. (2012) 6:64–73. 10.1016/j.provac.2012.04.009 149.CarrilloEFernandezLIbarra-MenesesAVSantosMLBNicoDde LucaPMet al.. F1"/>
  <result pre="16:213–7. 10.1016/S0169-4758(99)01623-310782082 152.UehlingerFDO'HandleyRMGreenwoodSJGuselleNJGaborLJVan VelsenCMet al.. Efficacy of vaccination in preventing" exact="giardiasis" post="in calves. Vet Parasitol. (2007) 146:182–8. 10.1016/j.vetpar.2007.01.01317350765"/>
 </snippets>
</snippetsTree>
